High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis

High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis

Paraschos Archontakis Barakakis,1 Thuonghien Tran,2 Jee Young You,3 Gabriel J Hernandez Romero,4 Vipul Gidwani,1 Fernando J Martinez,5 Spyridon Fortis2,6 1Northeast Internal Medicine Associates, LaGrange, IN, USA; 2Division of Pulmonary, Critical Care, and Occupational Medicine, Department of Intern...

Full description

Bibliographic Details
Main Authors:	Archontakis Barakakis P, Tran T, You JY, Hernandez Romero GJ, Gidwani V, Martinez FJ, Fortis S
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-04-01
Series:	International Journal of COPD
Subjects:	• chronic obstructive lung disease • acute copd exacerbation • mortality • pneumonia • inhaled corticosteroids
Online Access:	https://www.dovepress.com/high-versus-medium-dose-of-inhaled-corticosteroid-in-chronic-obstructi-peer-reviewed-fulltext-article-COPD

Similar Items

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
by: Park JW, et al.
Published: (2023-05-01)

Associated Factors of Pneumonia in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Apart from the Use of Inhaled Corticosteroids
by: Rosario Lineros, et al.
Published: (2023-04-01)

Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study
by: Heerfordt CK, et al.
Published: (2024-09-01)

A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease
by: Lee JH, et al.
Published: (2023-02-01)

Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History
by: Andrea S. Melani, et al.
Published: (2024-02-01)

Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey
by: Miravitlles M, et al.
Published: (2022-07-01)

Re “Inhaled Corticosteroid Particle Size and Risk of Hospitalization Rue to Exacerbations and All-Cause Mortality in Patients With Chronic Obstructive Respiratory Disease. A Nationwide Cohort Study”. Heerfordt et al [Letter]
by: Hubbard R, et al.
Published: (2025-02-01)

Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
by: Hirano R, et al.
Published: (2018-10-01)

Protective effect of inhaled corticosteroid on children with asthma with Mycoplasma pneumoniae pneumonia
by: Bing Wei, et al.
Published: (2022-08-01)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
by: Neches García V, et al.
Published: (2022-09-01)

The dose of inhaled corticosteroids in patients with COPD: when less is better
by: Izquierdo JL, et al.
Published: (2018-10-01)

Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study
by: Heerfordt CK, et al.
Published: (2023-03-01)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
by: Sicras Mainar A, et al.
Published: (2019-09-01)

A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
by: Marc Miravitlles, et al.
Published: (2017-11-01)

Inhaled Corticosteroids and the Lung Microbiome in COPD
by: Holly R. Keir, et al.
Published: (2021-09-01)

Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD
by: Yamauchi Y, et al.
Published: (2016-06-01)

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
by: Miravitlles M, et al.
Published: (2022-01-01)

Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction
by: Hyo Jin Lee, et al.
Published: (2024-01-01)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
by: Ye Jin Lee, et al.
Published: (2023-07-01)

Lack of Association between Inhaled Corticosteroid Use Based on the Exhaled Nitric Oxide and Acute Exacerbation of Chronic Obstructive Pulmonary Disease
by: Bo-Guen Kim, et al.
Published: (2024-07-01)

Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis
by: Wang Chun Kwok, et al.
Published: (2023-06-01)

The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD
by: Ricardo G. Figueiredo, et al.
Published: (2022-08-01)

Inhaled Corticosteroids May Not Affect the Clinical Outcomes of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
by: Min-Seok Chang, et al.
Published: (2024-07-01)

Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease – nationwide development from 1998 to 2018
by: Allan Klitgaard, et al.
Published: (2024-12-01)

Impact of patient compliance with inhaler therapy on chronic obstructive pulmonary disease severity: a rural tertiary care perspective
by: Nandakishore K. S., et al.
Published: (2025-02-01)

Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS
by: Price D, et al.
Published: (2024-01-01)

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
by: Trigueros JA, et al.
Published: (2022-11-01)

Impact of adherence to GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in a Swiss COPD cohort
by: Anja Jochmann, et al.
Published: (2012-03-01)

Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting
by: Whittaker HR, et al.
Published: (2019-05-01)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
by: Vogelmeier C, et al.
Published: (2017-02-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Withdrawal of Inhaled Corticosteroids from Patients with COPD; Effect on Exacerbation Frequency and Lung Function: A Systematic Review
by: Georgiou A, et al.
Published: (2024-06-01)

Radiographic Phenotypes Affect the Risk of Inhaled Corticosteroid-Associated Pneumonia in Patients with COPD
by: Lee HJ, et al.
Published: (2022-09-01)

Nebulized corticosteroids in the management of acute exacerbation of COPD
by: Gaude G, et al.
Published: (2010-01-01)

Association between inhaled corticosteroid use and risk of hyperglycemia in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
by: Fathur Nur Kholis, et al.
Published: (2023-01-01)

A Delphi Consensus Project to Capture Greek Experts’ Opinion on the Position of Triple Therapies in COPD: Why, When and to Whom
by: Papaioannou AI, et al.
Published: (2025-02-01)

Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study
by: Janwillem Kocks, et al.
Published: (2023-08-01)

Differences in the effectiveness of single, dual, and triple inhaled corticosteroid therapy for reducing future risk of severe asthma exacerbation: A systematic review and network meta-analysis
by: Akira Yamasaki, et al.
Published: (2024-06-01)

Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature
by: Caramori G, et al.
Published: (2019-05-01)

Exacerbations in COPD patients treated with Inhaled Corticosteroids/Long-acting β2 agonists combinations, switching to another combination drugs or inhaler device: A “real – world” study
by: Diego Sangiorgi, et al.
Published: (2017-01-01)